Gain an unbiased perspective of the market and its potential, independently assess launches, understand the patient journey and prescribers' perspectives, and gauge the impact of disruptive events.
Interactive on-site or virtual sessions with Spherix therapeutic experts, highlighting commercially relevant analyses, contextual data, and custom insights tailored to your business.
Fortify your strategy and tactics with our industry experts who are well-equipped to deliver strategic advisory services across the product lifecycle.
Transformation + Acceleration = Success
Plan and execute your launch with complete confidence. Create a strategic roadmap that aligns IT, data, operations, and compliance SOPs before you reach market.
Facilitate intelligent decision-making, improve customer engagement, and get the insights needed to drive successful business outcomes. Streamline key workflows to eliminate bottlenecks and reduce spend.
Harmonize disparate systems to achieve mutual success. Rationalize system integrations, eliminate redundancies, and migrate data and users with minimal friction.
With few treatment options for patients, hematologists look to pipeline agents such as Johnson & Johnson’s nipocalimab and Novartis’ ianalumab to improve patient outcomes, according
US retinal specialists identify 4D Molecular Therapeutics’ 4D-150, Adverum Biotechnologies’ Ixo-vec, and Johnson & Johnson’s JNJ-1887 as most likely pipeline candidates for prescription if approved.
Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab. Managing hidradenitis suppurativa (HS) effectively remains
Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line with the rollout of Dupixent
Impacts of Eohilia’s short-term 12-week label are still unfolding, but prescribers express interest in continuing consecutive treatment courses. EXTON, PA., July 18, 2024 – In
Epileptologists and general neurologists have different approaches to treating people with refractory epilepsy, according to the Market Dynamix: Adult Refractory Epilepsy (US) study conducted by
